ibritumomab tiuxetan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
chelating agents	4984	206181-63-7

Description:

Molecule	Description
Synonyms: ibritumomab tiuxetan (90Y) ibritumomab tiuxetan zevalin IDEC-Y2B8	90Y-labeled anti-CD20 monoclonal antibody for radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma Molecular weight: 660.50 Formula: C23H32N5O10SY CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

ibritumomab tiuxetan (90Y)
ibritumomab tiuxetan
zevalin
IDEC-Y2B8

90Y-labeled anti-CD20 monoclonal antibody for radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma

Molecular weight: 660.50
Formula: C23H32N5O10SY
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Jan. 16, 2004	EMA
Feb. 19, 2002	FDA	SPECTRUM PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Thrombocytopenia	99.64	37.68	50	1084	151107	63336781
Bone marrow failure	92.38	37.68	30	1104	29260	63458628
Progressive multifocal leukoencephalopathy	78.62	37.68	22	1112	12949	63474939
Stem cell transplant	71.02	37.68	14	1120	1808	63486080
Myelodysplastic syndrome	68.76	37.68	21	1113	16733	63471155
Neutropenia	50.70	37.68	34	1100	174971	63312917
Enterococcal infection	41.60	37.68	12	1122	7836	63480052
Pancytopenia	41.05	37.68	24	1110	96909	63390979

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelodysplastic syndrome	92.91	36.77	34	1500	19174	34936223
Meningitis tuberculous	90.87	36.77	17	1517	668	34954729
Mucosal inflammation	58.17	36.77	30	1504	38592	34916805
Venoocclusive liver disease	53.40	36.77	18	1516	7948	34947449
Herpes simplex	51.26	36.77	16	1518	5543	34949854
Progressive multifocal leukoencephalopathy	49.81	36.77	18	1516	9746	34945651
Acute myeloid leukaemia	48.51	36.77	21	1513	18249	34937148
Bone marrow failure	44.81	36.77	23	1511	29230	34926167
Thrombocytopenia	43.24	36.77	43	1491	156204	34799193
Stem cell transplant	36.81	36.77	10	1524	2129	34953268

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelodysplastic syndrome	134.83	31.59	47	2615	30254	79711472
Bone marrow failure	114.29	31.59	48	2614	51059	79690667
Progressive multifocal leukoencephalopathy	107.41	31.59	36	2626	20564	79721162
Thrombocytopenia	97.10	31.59	76	2586	265183	79476543
Stem cell transplant	92.20	31.59	22	2640	3682	79738044
Meningitis tuberculous	79.86	31.59	16	2646	1189	79740537
Cytomegalovirus infection	69.20	31.59	32	2630	42612	79699114
Neutropenia	65.64	31.59	63	2599	287647	79454079
Pancytopenia	63.77	31.59	49	2613	165696	79576030
Platelet count decreased	63.04	31.59	52	2610	194612	79547114
Acute graft versus host disease in intestine	60.60	31.59	16	2646	4025	79737701
White blood cell count decreased	58.26	31.59	49	2613	188239	79553487
Acute myeloid leukaemia	55.85	31.59	25	2637	30860	79710866
Multiple organ dysfunction syndrome	51.65	31.59	38	2624	120208	79621518
Acute graft versus host disease in skin	50.49	31.59	16	2646	7642	79734084
Respiratory failure	49.69	31.59	44	2618	180867	79560859
Venoocclusive liver disease	47.49	31.59	17	2645	11754	79729972
Mucosal inflammation	46.94	31.59	30	2632	75550	79666176
Herpes simplex	46.91	31.59	17	2645	12170	79729556
Sepsis	38.33	31.59	46	2616	269382	79472344
Aplasia	38.10	31.59	13	2649	7807	79733919
Enterococcal infection	35.91	31.59	15	2647	15645	79726081
Disease progression	35.70	31.59	37	2625	184325	79557401
Second primary malignancy	33.76	31.59	14	2648	14336	79727390
Neutrophil count decreased	32.23	31.59	26	2636	93933	79647793

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V10XX02	VARIOUS THERAPEUTIC RADIOPHARMACEUTICALS OTHER THERAPEUTIC RADIOPHARMACEUTICALS Various therapeutic radiopharmaceuticals
FDA MoA	N0000000205	Radiopharmaceutical Activity
FDA MoA	N0000175078	CD20-directed Antibody Interactions
FDA EPC	N0000175658	CD20-directed Radiotherapeutic Antibody

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Follicular non-Hodgkin's lymphoma	indication	308121000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
B-lymphocyte antigen CD20	Surface antigen	P11836	CD20_HUMAN	ANTIBODY BINDING	Kd	7.85		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D04489	KEGG_DRUG
4021301	VUID
N0000148737	NUI
4021301	VANDF
CHEMBL2108667	ChEMBL_ID
CHEMBL1201606	ChEMBL_ID
C422802	MESH_SUPPLEMENTAL_RECORD_UI
6777	IUPHAR_LIGAND_ID
DB00078	DRUGBANK_ID
262323	RXNORM
17128	MMSL
d04845	MMSL
009576	NDDF
385546007	SNOMEDCT_US
385548008	SNOMEDCT_US
C0877880	UMLSCUI
7873	INN_ID
74890578	PUBCHEM_CID
4Q52C550XK	UNII

Pharmaceutical products:

None